請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38276完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林淑萍(Shwu-Bin Lin) | |
| dc.contributor.author | Ue-Min Chang | en |
| dc.contributor.author | 張郁旻 | zh_TW |
| dc.date.accessioned | 2021-06-13T16:29:19Z | - |
| dc.date.available | 2006-08-02 | |
| dc.date.copyright | 2005-08-02 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-07-12 | |
| dc.identifier.citation | References
Alcorta,D.A., Xiong,Y., Phelps,D., Hannon,G., Beach,D., and Barrett,J.C. (1996). Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. U. S. A 93, 13742-13747. Bains,J.S. and Shaw,C.A. (1997). Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 25, 335-358. Baur,J.A., Zou,Y., Shay,J.W., and Wright,W.E. (2001). Telomere position effect in human cells. Science 292, 2075-2077. Ben-Porath,I. and Weinberg,R.A. (2004). When cells get stressed: an integrative view of cellular senescence. J. Clin. Invest 113, 8-13. Bode,A.M. and Dong,Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4, 793-805. Bulavin,D.V., Phillips,C., Nannenga,B., Timofeev,O., Donehower,L.A., Anderson,C.W., Appella,E., and Fornace,A.J., Jr. (2004). Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet. 36, 343-350. Burden,D.A. and Osheroff,N. (1998). Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400, 139-154. Chen,H.L., Lu,C.Y., Hsu,Y.H., and Lin,J.J. (2004). Chromosome positional effects of gene expressions after cellular senescence. Biochem. Biophys. Res. Commun. 313, 576-586. Chen,J., Small-Howard,A., Yin,A., and Berry,M.J. (2005). The responses of Ht22 cells to oxidative stress induced by buthionine sulfoximine (BSO). BMC. Neurosci. 6, 10. Cong,Z. and Lin,Z.B. (1981). The pharmacological study of Lingzhi (Ganoderma lucidum) and the research of therapeutical principle of 'Fuzhengguben' in Traditional Chinese medicine. J Beijing Med Coll 13, 6-10. Deng,Q., Liao,R., Wu,B.L., and Sun,P. (2004). High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J. Biol. Chem. 279, 1050-1059. Di,L.A., Linke,S.P., Clarkin,K., and Wahl,G.M. (1994). DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8, 2540-2551. Dimri,G.P., Lee,X., Basile,G., Acosta,M., Scott,G., Roskelley,C., Medrano,E.E., Linskens,M., Rubelj,I., Pereira-Smith,O., and . (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A 92, 9363-9367. DiNardo,S., Voelkel,K., and Sternglanz,R. (1984). DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc. Natl. Acad. Sci. U. S. A 81, 2616-2620. el-Mekkawy,S., Meselhy,M.R., Nakamura,N., Tezuka,Y., Hattori,M., Kakiuchi,N., Shimotohno,K., Kawahata,T., and Otake,T. (1998). Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum. Phytochemistry 49, 1651-1657. Famulski,K.S. and Halloran,P.F. (2005). Molecular events in kidney ageing. Curr. Opin. Nephrol. Hypertens. 14, 243-248. Fletcher,T.M. (2005). Telomerase: a potential therapeutic target for cancer. Expert. Opin. Ther. Targets. 9, 457-469. Gao,J.J., Min,B.S., Ahn,E.M., Nakamura,N., Lee,H.K., and Hattori,M. (2002). New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chem. Pharm. Bull. (Tokyo) 50, 837-840. Gerdes,J., Schwab,U., Lemke,H., and Stein,H. (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 31, 13-20. Harker,W.G., Slade,D.L., Dalton,W.S., Meltzer,P.S., and Trent,J.M. (1989). Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49, 4542-4549. Harker,W.G., Slade,D.L., Drake,F.H., and Parr,R.L. (1991). Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30, 9953-9961. Hayflick,L. (1965). The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614-636. Hossain,M.S., Kurokawa,K., Akimitsu,N., and Sekimizu,K. (2004). DNA topoisomerase II is required for the G0-to-S phase transition in Drosophila Schneider cells, but not in yeast. Genes Cells 9, 905-917. Ishida,R., Sato,M., Narita,T., Utsumi,K.R., Nishimoto,T., Morita,T., Nagata,H., and Andoh,T. (1994). Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J. Cell Biol. 126, 1341-1351. Itahana,K., Campisi,J., and Dimri,G.P. (2004). Mechanisms of cellular senescence in human and mouse cells. Biogerontology. 5, 1-10. Kimura,Y., Taniguchi,M., and Baba,K. (2002). Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res. 22, 3309-3318. Krzystyniak,K.L. (2002). Current strategies for anticancer chemoprevention and chemoprotection. Acta Pol. Pharm. 59, 473-478. Li,C.H., Chen,P.Y., Chang,U.M., Kan,L.S., Fang,W.H., Tsai,K.S., and Lin,S.B. (2005). Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells. Life Sci. 77, 252-265. Lin,S.B., Li,C.H., Lee,S.S., and Kan,L.S. (2003). Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci. 72, 2381-2390. Lloyd,A.C. (2002). Limits to lifespan. Nat. Cell Biol. 4, E25-E27. Min,B.S., Gao,J.J., Hattori,M., Lee,H.K., and Kim,Y.H. (2001). Anticomplement activity of terpenoids from the spores of Ganoderma lucidum. Planta Med 67, 811-814. Min,B.S., Gao,J.J., Nakamura,N., and Hattori,M. (2000). Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells. Chem. Pharm. Bull. (Tokyo) 48, 1026-1033. Mizushina,Y., Iida,A., Ohta,K., Sugawara,F., and Sakaguchi,K. (2000). Novel triterpenoids inhibit both DNA polymerase and DNA topoisomerase. Biochem. J. 350 Pt 3, 757-763. Muller,M.T., Pfund,W.P., Mehta,V.B., and Trask,D.K. (1985). Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J. 4, 1237-1243. Naka,K., Tachibana,A., Ikeda,K., and Motoyama,N. (2004). Stress-induced premature senescence in hTERT-expressing ataxia telangiectasia fibroblasts. J Biol. Chem. 279, 2030-2037. Noda,A., Ning,Y., Venable,S.F., Pereira-Smith,O.M., and Smith,J.R. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211, 90-98. Pommier,Y., Pourquier,P., Fan,Y., and Strumberg,D. (1998). Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400, 83-105. Roninson,I.B., Broude,E.V., and Chang,B.D. (2001). If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 4, 303-313. Schluter,C., Duchrow,M., Wohlenberg,C., Becker,M.H., Key,G., Flad,H.D., and Gerdes,J. (1993). The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J. Cell Biol. 123, 513-522. Sharpless,N.E. and DePinho,R.A. (2004). Telomeres, stem cells, senescence, and cancer. J. Clin. Invest 113, 160-168. Shay,J.W. and Roninson,I.B. (2004). Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-2933. Shiao,M.S. (2003). Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem. Rec. 3, 172-180. Smith,J. (2002). Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 12, 404-406. Stein,G.H., Drullinger,L.F., Soulard,A., and Dulic,V. (1999). Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell Biol. 19, 2109-2117. Syrovets,T., Buchele,B., Gedig,E., Slupsky,J.R., and Simmet,T. (2000). Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. Mol. Pharmacol. 58, 71-81. Toth,J.O., Luu,B., and Ourisson,G. (1986). Les acides gadoderiques I a Z: triterpenes cytotoxiques de Ganoderma lucidum (polyporacee). Tetrahedron Lett. 24, 1081-1084. Toussaint,O., Dumont,P., Remacle,J., Dierick,J.F., Pascal,T., Frippiat,C., Magalhaes,J.P., Zdanov,S., and Chainiaux,F. (2002). Stress-induced premature senescence or stress-induced senescence-like phenotype: one in vivo reality, two possible definitions? ScientificWorldJournal. 2, 230-247. Toussaint,O., Medrano,E.E., and von,Z.T. (2000). Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp. Gerontol. 35, 927-945. Uggla,B., Mollgard,L., Stahl,E., Mossberg,L.L., Karlsson,M.G., Paul,C., and Tidefelt,U. (2001). Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells. Leuk. Res. 25, 961-966. Venable,M.E., Lee,J.Y., Smyth,M.J., Bielawska,A., and Obeid,L.M. (1995). Role of ceramide in cellular senescence. J. Biol. Chem. 270, 30701-30708. Wang,J.C. (1996). DNA topoisomerases. Annu. Rev. Biochem. 65, 635-692. Wang,J.C. (1998). Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys. 31, 107-144. Wu,T.S., Shi,L.S., and Kuo,S.C. (2001). Cytotoxicity of Ganoderma lucidum triterpenes. J Nat. Prod. 64, 1121-1122. Yan,X., Zou,J., and Xie,G. (1999). Traditional Chinese Medicines: Molecular structures, matural sources, and applications. Ashgate Publishing Company, USA p.722, p.730. Yeung,H.W., Lu,Q.-Y., Zhang,Q., and Go,V.L.W. (2004). Chemical and biochemical basis of the potential anti-tumor properties of Ganoderma lucidum. Current Topics in Nutraceutical Research 2, 67-77. Zhu,H.S., Yang,X.L., Wang,L.B., Zhao,D.X., and Chen,L. (2000). Effects of extracts from sporoderm-broken spores of Ganoderma lucidum on HeLa cells. Cell Biol. Toxicol. 16, 201-206. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38276 | - |
| dc.description.abstract | 靈芝醇(Ganoderiol F；841)是萃取自鹿角靈芝具有四環結構的三帖類。在本實驗中發現，841可同時抑制拓樸異構酶I與拓樸異構酶IIα的活性。在肝癌(HepG2, Hep3B, Huh7)及血癌(K562)細胞的研究中，841可立即抑制細胞內DNA的合成，使細胞生長停止，而對正常的肺纖維母細胞影響較小，甚至完全不會影響到週邊血細胞的存活。更進一步發現，841可誘導肝癌細胞(HepG2)走向老化的命運。在誘導老化的分子機制上，我們觀察到p21及p16的表現量增加、p38及p53被活化、以及p53的負調節因子：SIRT-1與細胞週期調節因子：cyclin D1的減少。這是第一篇指出841可誘導癌細胞老化的研究。因此，具有選擇性抑制癌細胞及誘導老化能力的841也許將來能應用於癌症的治療上。另一方面，低劑量的841雖然不會影響到癌細胞的生長，但是卻可以抑制細胞內端粒酶的mRNA表現，也可降低Buthionine sulfoximine所造成的細胞毒性。由這些實驗推測，低劑量的841也許可以當作化學預防藥物來抑制細胞的癌化。 | zh_TW |
| dc.description.abstract | Ganoderiol F (841), a tetracyclic triterpene isolated from Ganoderma amboinense, was found to be inhibitors of both topoisomerase I and topoisomerase IIα. Treatment of human hepatoma HepG2, Hep3B, Huh7 cells, and leukemia K562 cells with 841 resulted in immediate inhibition of DNA synthesis and halt of cell growth. On the other hand, the growth of normal lung fibroblast MRC5 cells were less affected and peripheral blood mononuclear cells were unaffected by 841. Furthermore, a senescent phenotype was detected in 841-treated HepG2 cells. Molecular events of senescence, including increase of p21 and p16, activation of p38 and p53 and the decrease of SIRT-1 as well as cyclin D1, were observed. Our study is the first report about 841 functioning as a senescence inducer in cancer cells and the tumor selective cytostatic effect and senescence induction capability of 841 might have anticancer implications. Low dosage of 841 (<1 μM) did not affect the viability of HepG2 cells but caused a significant decrease in the mRNA expression of hTERT, a reverse transcriptase subunit of telomerase, and detoxification in buthionine sulfoximine-treated cell, suggesting that low-dose of 841 may function as chemopreventive agent and inhibit tumorigenesis. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T16:29:19Z (GMT). No. of bitstreams: 1 ntu-94-R92424018-1.pdf: 4031072 bytes, checksum: e44aa767b50d05958f47809313dfccf8 (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | Figure and Table Contents ---------------------------- 02
Abbreviations ------------------------------------- 03 English Abstract ------------------------------------- 04 Chinese Abstract ------------------------------------- 05 Introduction ------------------------------------- 06 Materials and Methods ---------------------------- 10 Results ----------------------------------------------- 22 Discussion ------------------------------------- 26 References ------------------------------------- 31 Table ---------------------------------------------- 37 Figures ---------------------------------------------- 38 Supplementary Table ---------------------------- 50 Supplementary Figures ---------------------------- 51 Appendix ---------------------------------------------- 59 | |
| dc.language.iso | en | |
| dc.subject | 癌症 | zh_TW |
| dc.subject | 靈芝醇 | zh_TW |
| dc.subject | 三帖類 | zh_TW |
| dc.subject | 拓樸異構酶 | zh_TW |
| dc.subject | 老化 | zh_TW |
| dc.subject | topoisomerase | en |
| dc.subject | cancer | en |
| dc.subject | senescence | en |
| dc.subject | Ganoderiol F | en |
| dc.subject | triterpene | en |
| dc.title | 靈芝醇抗癌機制的研究：抑制拓樸異構酶及引導肝癌細胞走向老化 | zh_TW |
| dc.title | Ganoderiol F inhibits topoisomerases and induces senescence of hepatoma cells, a strategy for cancer therapy | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 甘魯生,陳進庭,林亮音 | |
| dc.subject.keyword | 靈芝醇,三帖類,拓樸異構酶,老化,癌症, | zh_TW |
| dc.subject.keyword | Ganoderiol F,triterpene,topoisomerase,senescence,cancer, | en |
| dc.relation.page | 62 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-07-13 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 醫事技術學研究所 | zh_TW |
| 顯示於系所單位： | 醫學檢驗暨生物技術學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 未授權公開取用 | 3.94 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。